Andrew T McAfee

Summary

Affiliation: Cancer Prevention Program
Country: USA

Publications

  1. ncbi Empirically derived subgroups in rheumatoid arthritis: association with single-nucleotide polymorphisms on chromosome 6
    Marsha A Wilcox
    i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, Massachusetts 02431, USA
    BMC Proc 1:S20. 2007
  2. ncbi The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy
    Andrew T McAfee
    i3 Drug Safety, Newton, MA 02466, USA
    Pharmacoepidemiol Drug Saf 15:444-53. 2006
  3. ncbi The incidence of first provoked and unprovoked seizure in pediatric patients with and without psychiatric diagnoses
    Andrew T McAfee
    i3 Drug Safety, Waltham, Massachusetts 02451, USA
    Epilepsia 48:1075-82. 2007
  4. ncbi Coronary heart disease outcomes in patients receiving antidiabetic agents
    Andrew T McAfee
    i3 Drug Safety, Newton, Massachusetts 02451, USA
    Pharmacoepidemiol Drug Saf 16:711-25. 2007
  5. ncbi The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database
    Najat Ziyadeh
    i3 Drug Safety, Waltham, Massachusetts 02451, USA
    Clin Ther 31:2665-77. 2009
  6. ncbi Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP)
    Cheryl Enger
    i3 Drug Safety, Ann Arbor, MI 48108, USA
    Ann Hepatol 10:188-95. 2011
  7. ncbi The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database
    Andrew T McAfee
    1i3 Drug Safety, Waltham, Massachusetts, USA
    Curr Drug Saf 3:123-31. 2008
  8. ncbi Pharmacoepidemiology safety study of fibrate and statin concomitant therapy
    Cheryl Enger
    Epidemiology, i3 Drug Safety, Waltham, Massachusetts, USA
    Am J Cardiol 106:1594-601. 2010
  9. ncbi A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications
    Andrew T McAfee
    OptumInsight formerly i3 Drug Safety, Waltham, MA, USA Department of Emergency Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 22:386-93. 2013
  10. ncbi Comorbidities in patients with persistent or chronic immune thrombocytopenia
    Cheryl Enger
    i3 Drug Safety, 5430 Data Court, Ann Arbor, MI 48108, USA
    Int J Hematol 92:289-95. 2010

Detail Information

Publications13

  1. ncbi Empirically derived subgroups in rheumatoid arthritis: association with single-nucleotide polymorphisms on chromosome 6
    Marsha A Wilcox
    i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, Massachusetts 02431, USA
    BMC Proc 1:S20. 2007
    ..It will be important to replicate the subgroup structure and the association findings in an independent sample...
  2. ncbi The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy
    Andrew T McAfee
    i3 Drug Safety, Newton, MA 02466, USA
    Pharmacoepidemiol Drug Saf 15:444-53. 2006
    ..The purpose of this study was to compare incidence rates of hospitalization associated with rhabdomyolysis, myopathy, renal, or hepatic dysfunction, and of in-hospital death, between initiators of rosuvastatin and other statins...
  3. ncbi The incidence of first provoked and unprovoked seizure in pediatric patients with and without psychiatric diagnoses
    Andrew T McAfee
    i3 Drug Safety, Waltham, Massachusetts 02451, USA
    Epilepsia 48:1075-82. 2007
    ..To estimate the rate of new-onset afebrile provoked and unprovoked seizure in a general pediatric population and subgroups of patients with and without psychiatric diagnoses other than attention deficit hyperactivity disorder (ADHD)...
  4. ncbi Coronary heart disease outcomes in patients receiving antidiabetic agents
    Andrew T McAfee
    i3 Drug Safety, Newton, Massachusetts 02451, USA
    Pharmacoepidemiol Drug Saf 16:711-25. 2007
    ..There is conflicting evidence on the reduction of cardiovascular risk in diabetic patients treated with oral antidiabetic agents...
  5. ncbi The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database
    Najat Ziyadeh
    i3 Drug Safety, Waltham, Massachusetts 02451, USA
    Clin Ther 31:2665-77. 2009
    ..Although recent meta-analyses suggest there is an increased risk of myocardial infarction (MI) among rosiglitazone users, these findings were not supported by data from other studies...
  6. ncbi Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP)
    Cheryl Enger
    i3 Drug Safety, Ann Arbor, MI 48108, USA
    Ann Hepatol 10:188-95. 2011
    ..HBLAs were significantly associated with male gender, liver disease, and several other comorbidities, thus, distinguishing drug-induced liver injury in this population is clinically challenging...
  7. ncbi The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database
    Andrew T McAfee
    1i3 Drug Safety, Waltham, Massachusetts, USA
    Curr Drug Saf 3:123-31. 2008
    ..To estimate the rate of new-onset seizure in ADHD patients in relation to ADHD pharmacotherapy...
  8. ncbi Pharmacoepidemiology safety study of fibrate and statin concomitant therapy
    Cheryl Enger
    Epidemiology, i3 Drug Safety, Waltham, Massachusetts, USA
    Am J Cardiol 106:1594-601. 2010
    ..The risk for pancreatitis was higher in patients treated with fenofibrate, whether in combination with statins or alone...
  9. ncbi A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications
    Andrew T McAfee
    OptumInsight formerly i3 Drug Safety, Waltham, MA, USA Department of Emergency Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 22:386-93. 2013
    ..This retrospective cohort analysis evaluated risk of seizures among pediatric patients naïve to ADHD medication therapy, with exposure to atomoxetine relative to stimulant medications...
  10. ncbi Comorbidities in patients with persistent or chronic immune thrombocytopenia
    Cheryl Enger
    i3 Drug Safety, 5430 Data Court, Ann Arbor, MI 48108, USA
    Int J Hematol 92:289-95. 2010
    ..Patients with persistent or chronic ITP are at increased risk for several comorbidities including hematologic malignancies, relative to a matched comparison cohort...
  11. ncbi Studies of diabetes, thiazolidinediones, and coronary heart disease
    Alexander M Walker
    Pharmacoepidemiol Drug Saf 16:1313-4; author reply 1314-6. 2007
  12. ncbi Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme
    Saga Johansson
    AstraZeneca R and D Molndal, Sweden
    Pharmacoepidemiol Drug Saf 15:454-61. 2006
    ..This article is an overview of the rationale and methodology of the rosuvastatin pharmacoepidemiology programme...
  13. ncbi The contribution of the subjective component of the Canadian Pulmonary Embolism Score to the overall score in emergency department patients
    Christopher Kabrhel
    Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Acad Emerg Med 12:915-20. 2005
    ..However, research suggests that subjective gestalt performs similarly to the CPES, and the influence of the subjective question on the predictive value of the CPES is not clear...